$15.4 M

DMPI Mkt cap, 28-Jan-2021
Del Mar Pharmaceuticals Net income (Q2, 2021)-5.4 M
Del Mar Pharmaceuticals Cash, 31-Dec-202017.2 M
Del Mar Pharmaceuticals EV-1.3 M

Del Mar Pharmaceuticals Income Statement

Annual

USDFY, 2012FY, 2015FY, 2017FY, 2018FY, 2019

Revenue

R&D expense

5.0m

General and administrative expense

7.3k3.3m

Operating expense total

7.3k8.3m33.2k60.7k

EBIT

(18.9k)

Interest expense

2.1k

Interest income

363.0

Net Income

(18.9k)4.8m8.1m11.1m8.0m

Del Mar Pharmaceuticals Balance Sheet

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

1.8k4.1m4.8m1.8m6.6m6.0m3.7m2.4m

Accounts Receivable

11.1k

Prepaid Expenses

170.9k234.6k245.0k1.2m1.0m355.6k

Current Assets

7.9m7.0m2.9m

Total Assets

1.8k4.3m5.0m2.6m7.9m7.1m2.9m

Accounts Payable

249.5k244.9k762.3k626.0k1.2m1.5m1.7m2.0m

Short-term debt

33.1k

Current Liabilities

249.5k299.9k853.1k1.3m1.6m

Long-term debt

272.4k276.4k28.1k1.1k

Total Debt

272.4k276.4k61.2k1.1k

Total Liabilities

10.0k5.1m4.1m2.1m1.3m1.6m2.7m

Common Stock

3.9k31.5k36.0k39.5k14.5k23.0k11.5k

Preferred Stock

278.5k

Additional Paid-in Capital

45.6k8.8m13.3m17.5m36.7m43.2m51.0m56.6m

Retained Earnings

(23.5m)(41.1m)(52.4m)(60.6m)(69.7m)

Total Equity

(8.2k)(818.0k)880.5k511.9k6.6m5.4m263.2k

Debt to Equity Ratio

0 x0 x

Debt to Assets Ratio

0 x0 x

Financial Leverage

-0.2 x-5.3 x5.7 x5 x1.2 x1.3 x11.2 x

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q1, 2013Q2, 2013Q3, 2013Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q2, 2021

Cash

6.8k805.02.8k609.04.0k7.5m6.3m5.2m4.3m4.0m3.0m2.8m2.0m937.4k4.8m3.4m2.1m13.2m11.0m8.5m3.9m3.7m2.2m8.1m6.3m5.0m17.2m

Accounts Receivable

13.8k

Prepaid Expenses

83.5k221.3k210.5k162.2k155.9k357.6k191.6k167.5k85.3k177.3k130.8k119.8k1.2m1.1m1.1m831.5k306.7k240.1k223.7k123.0k114.9k551.0k

Current Assets

3.4m3.0m2.1m1.1m5.0m3.6m2.3m14.4m12.2m9.6m4.7m4.0m2.4m8.4m6.5m5.1m17.7m

PP&E

172.0k

Total Assets

6.8k805.02.8k609.04.0k7.7m6.5m5.4m4.5m4.1m2.2m1.2m5.0m3.6m2.3m14.4m12.2m9.7m4.7m4.0m2.5m8.4m6.5m5.1m20.5m

Accounts Payable

578.9k431.2k210.6k294.0k256.5k486.2k372.8k479.1k646.9k405.8k515.6k791.8k1.4m1.8m1.9m909.9k1.1m1.1m1.1m750.8k1.1m2.0m

Dividends Payable

2.1k4.2k

Short-term debt

296.1k2.1k(157.1k)589.095.0473.0k

Current Liabilities

10.0k875.0k667.7k427.8k335.7k294.2k529.7k411.5k535.8k676.0k482.3k721.0k1.0m1.5m2.2m2.0m1.1m1.3m1.2m2.7m

Long-term debt

266.3k268.3k270.3k248.7k4.1k5.5k1.3k76.0265.0

Total Debt

562.4k268.3k270.3k274.4k91.5k4.7k5.5k1.3k76.0265.0473.0k

Total Liabilities

4.9k13.0k19.6k9.7m14.2m5.7m4.0m2.0m2.2m3.5m2.1m1.8m1.1m892.2k1.1m1.5m2.2m2.0m1.1m1.3m1.2m1.3m1.0m1.4m2.9m

Common Stock

6.0k3.9k3.9k3.9k3.9k30.6k31.2k31.5k36.8k38.6k39.5k43.7k44.3k44.3k11.4k11.5k11.7k22.6k22.6k22.9k23.0k26.1k2.6k11.4k11.4k11.4k25.0k

Preferred Stock

278.5k278.5k278.5k278.5k278.5k278.5k

Additional Paid-in Capital

43.6k45.6k45.6k45.6k45.6k6.5m7.6m8.4m14.0m16.6m17.5m18.6m21.7m21.8m30.5m30.8m31.5m43.0m43.2m43.7m43.4m46.8m47.0m56.1m56.3m56.4m93.6m

Retained Earnings

(42.6k)(53.5k)(56.6k)(22.7m)(20.2m)(22.9m)(24.0m)(34.8m)(36.3m)(38.4m)(43.8m)(47.0m)(50.0m)(54.5m)(56.3m)(58.0m)(62.2m)(63.9m)(65.9m)(97.8m)

Total Equity

6.8k(4.1k)(7.2k)(12.3k)(15.6k)(2.0m)(7.7m)(304.3k)520.9k2.1m1.2m(514.5k)116.7k(687.6k)4.0m2.7m1.2m12.9m10.0m7.7m3.7m2.8m1.3m7.0m5.5m3.7m17.6m

Debt to Equity Ratio

0.5 x0.1 x0 x0 x0 x0 x0 x

Debt to Assets Ratio

0.1 x0 x0 x0 x0 x0 x0 x

Financial Leverage

1 x-0.2 x-0.4 x0 x-0.3 x-3.8 x-0.8 x-17.7 x8.6 x2 x18.7 x-1.7 x1.3 x1.3 x1.9 x1.1 x1.2 x1.3 x1.3 x1.5 x2 x1.2 x1.2 x1.4 x1.2 x

Del Mar Pharmaceuticals Cash Flow

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(18.9k)(8.3m)(2.8m)(4.8m)(8.9m)8.1m(11.1m)(8.0m)(9.1m)

Depreciation and Amortization

10.3k16.7k24.5k16.3k10.0k

Accounts Receivable

(5.0k)

Accounts Payable

2.5k(537.2k)104.4k517.4k(178.3k)598.3k295.8k202.0k206.6k

Cash From Operating Activities

(11.4k)(5.5m)(1.9m)(3.9m)(5.1m)(8.0m)(9.9m)(6.3m)(7.9m)

Cash From Investing Activities

(16.8k)(21.0k)(12.6k)

Dividends Paid

(8.4k)(8.4k)(8.4k)(8.4k)(8.4k)

Cash From Financing Activities

7.5k9.6m2.5m847.8k9.6m8.5m9.2m4.1m6.6m

Net Change in Cash

(3.9k)4.1m622.9k(3.0m)4.4m428.8k(614.0k)(2.3m)(1.3m)

Interest Paid

Income Taxes Paid

Del Mar Pharmaceuticals Ratios

USDQ1, 2012

Financial Leverage

1 x